All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
7 warning events since 2017; the latest 2026-03-25.
From the record
Longeveron Inc.'s filings since 2017 show 7 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2026-03-25); an auditor change (8-K item 4.01, 2 times, the latest 2025-03-14) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+30% a year over 3 filed years; profitable in 0 of 3.
From the record
Longeveron Inc.'s 3 filed years say what it did: revenue went from $709 thousand in fiscal 2023 to $1 million in fiscal 2025, up 30% a year; it rose in 1 of 2 years; the deepest fall was 50% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 3 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 9.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Longeveron Inc.'s shareholder treatment is put at 9.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 5% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -400%: lost 400¢ per shareholder dollar. Leverage 45%: owes 45¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Longeveron Inc. lost about 400 cents for every dollar of shareholders' money, and gross profitability: its products earned about 8 cents per dollar of everything the company owns. Leverage: it owed about 45 cents per dollar of assets, and net share issuance: its share count grew 86.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 40% of 315 in its family; net margin -1893.6%.
From the record
Longeveron Inc.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2025 ranks in the bottom 24% by size; a net margin of -1893.6% ranks in the bottom 24%; revenue growth of 30% a year over the last 2 filed years ranks in the top 30% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 9% of 315 in its family for leadership; chief executive since 2026.
From the record
Longeveron Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Willard, Stephen H (Chief Executive Officer, as filed), filing under that title since 2026-03-13, 8 months (bottom 10% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 1.6 years (bottom 5%); 16 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 13%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 48% of 273 in its family for room to expand.
From the record
Longeveron Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $5 million against no long-term debt tagged leaves 45.4% of its assets as net cash, top 35% of its family; cash from operations less capital spending is -1575.5% of revenue (bottom 19%); a gross margin of 67% (bottom 45%); research spending of 1004.3% of revenue (top 21%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 44% of 306 in its family for growth drivers.
From the record
Longeveron Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 30% a year over the last three filed years against 30% over all 3, speeding up (top 40% of its family); the newest year grew -49.9% (bottom 16%); research spending grew 8.7% a year (top 41%); capital spending grew -24.5% a year (bottom 41%) (its annual reports). Longeveron Inc. reported 3 product lines in fiscal 2025: Clinical Trial Revenue at $954 thousand (80%), Contract Manufacturing Revenue at $222 thousand (19%), Contract Manufacturing Lease Revenue at $23 thousand (2%); 0 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 5.3/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Longeveron Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made